Latest Content

This study found that certain characteristics in linked electronic health record data across episodes of care can help identify patients with Alzheimer disease and related dementias at high risk of 30-day readmissions.

Fuzuloparib extended progression-free survival, regardless of the addition of apatinib in patients with newly diagnosed advanced ovarian cancer.

This year's top inflammation article highlighted the first FDA-approved treatment for patients with bronchiectasis.

Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as the positive impact of RSV vaccination in older individuals.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

The conference focused on how to improve eye care across the country, including new methods of treating dry eye and utilizing new technologies to catch myopia earlier.

Patients with DLBCL who were treated with R-CHOP and quickly relapsed or were refractory to therapy had poor outcomes on second-line therapy.

Interim GLOVe trial results show that the frontline combination of glofitamab, lenalidomide, and venetoclax induces rapid, deep, and predominantly MRD-negative remissions in high-risk mantle cell lymphoma with manageable toxicity.

Federal policy changes, the push for fair pricing, and growing competition in the drug pipeline were major topics at this year’s meeting.